A prospective observational study of the inflammatory profile of Mepolizumab EXacerbations in participants with severe refractory eosinophilic asthma (the MEX study). (2021)

First Author: McDowell PJ
Attributed to:  United Kingdom Refractory Asthma Stratification Programme (RASP-UK) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Publication URI: https://www.sciencedirect.com/science/article/pii/S2213260021000047?via%3Dihub

Type: Journal Article/Review

Volume: 9

Parent Publication: Lancet Respir Med

Issue: 10